Pulido ZT

Language: Spanish
References: 14
Page: 349-352
PDF size: 0. Kb.

ABSTRACT

Pulmonary arterial hypertension is an uncommon, progressive and potentially fatal disease. Recent research has uncovered several biochemical abnormalities that have allowed the development for new therapies. Apart from conventional therapy (digoxin, oxygen, anticoagulation), our armamentarium includes Epoprostenol, calcium-channel blockers, lung transplantation, atrial septostomy, and more recently, Treprostinil, Iloprost and Bosentan. These drugs have proved an improvement in exercise tolerance and quality of life in patients with this disease

REFERENCES

1. Rubin LJ: Primary Pulmonary Hypertension. N Eng J Med 1998; 336: 111-117.

2. Sandoval J, Bauerle O, Palomar A, Gómez A, Martínez-Guerra ML, Mesa S, et al: Survival in primary pulmonary hypertension: validation of a prognostic equation. Circulation 1994; 89: 1733-1744.

3. Rich S, Kaufman E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Eng J Med 1992; 327: 76-81.

4. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Eng J Med 1996; 334: 296-301.

5. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: The impact of Epoprostenol therapy. Circulation 2002; 106: 1477-1482.

6. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC et al: Continuous infusion of Treprostinil, a Prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 800-804.

7. Olschewski H, Simonneau G, Galie N, Higenbottam T, Neaeije R, Rubin LJ, et al: Inhaled Iloprost for severe pulmonary hypertension. N Eng J Med 2002; 347: 322-329.

8. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al: Expression of Endothelin-1 in the lungs of patients with pulmonary hypertension. N Eng J Med 1993; 328: 1732-1739.

9. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al: Bosentan therapy for pulmonary arterial hypertension. N Eng J Med 2002; 346: 896-903.

10. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al: Effects of the oral endothelin-receptor antagonist Bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380-1386.

11. Pasque MK, Trulock EP, Cooper JD, Triantafillou AN, Huddleston CB, Rosenbloom M, et al: Single lung transplantation for pulmonary hypertension. Single Institution experience in 34 patients. Circulation 1995; 92: 2252-2258.

12. Sandoval J, Rothman A, Pulido T: Atrial septostomy for pulmonary hypertension. Clin Chest Med 2001; 22: 547-560.

13. Barst RJ, McGoon M, McLaughlin V, Tapson V, Oudiz R, Shapiro S, et al: Beraprost therapy for pulmonary hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.

14. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S: Oral Sildenafil is an effective and specific vasodilator in patients with pulmonary arterial hypertension: comparison with nitric oxide. Circulation 2002; 105: 2398-2403.